NCT05429775View on ClinicalTrials.gov

In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

December 26, 2018

Primary Completion Date

January 29, 2019

Study Completion Date

January 29, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

Budesonide

single dose of 2 mg oral suspension formulation administered orally under fasting conditions

Trial Locations (1)

NG11 6JS

Sandoz Investigative Site, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sandoz

INDUSTRY